Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Herpes-Zoster like rash; This non-serious case was reported by a physician via sales rep and described the occurrence of vesicular rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, 12 months after receiving Shingrix and Shingrix, the patient experienced vesicular rash (Verbatim: Herpes-Zoster like rash). The outcome of the vesicular rash was resolved. The reporter considered the vesicular rash to be related to Shingrix and Shingrix. The company considered the vesicular rash to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 09-APR-2025 The Healthcare professional shared his wife developed a minor Herpes-Zoster like rash that appeared even after having gotten both doses of Shingrix, approximately 12-18 months ago.